LBT Stock Overview
Engages in the research, development, and commercialization of technology solutions for medical industry in Australia, the United States, Sweden, the United Kingdom, and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Clever Culture Systems Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.017 |
| 52 Week High | AU$0.038 |
| 52 Week Low | AU$0.009 |
| Beta | 1.68 |
| 11 Month Change | 13.33% |
| 3 Month Change | 21.43% |
| 1 Year Change | -10.53% |
| 33 Year Change | -81.72% |
| 5 Year Change | -90.00% |
| Change since IPO | -92.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| LBT | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -10.5% | 2.1% | 0.8% |
| 1Y | -10.5% | 14.7% | 18.1% |
Return vs Industry: LBT underperformed the Australian Medical Equipment industry which returned 16.5% over the past year.
Return vs Market: LBT underperformed the Australian Market which returned 18.4% over the past year.
Price Volatility
| LBT volatility | |
|---|---|
| LBT Average Weekly Movement | 12.9% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: LBT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: LBT's weekly volatility has decreased from 26% to 13% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 19 | Brent Barnes | www.lbtinnovations.com |
Clever Culture Systems Limited engages in the research, development, and commercialization of technology solutions for medical industry in Australia, the United States, Sweden, the United Kingdom, and Germany. The company offers Automated Plate Assessment System (APAS) Independence, a solution that automates the imaging, analysis, and interpretation of microbiology culture plates primarily for microbiology laboratories and pharmaceutical manufacturing sector; APAS Analysis Modules, a software algorithm that enables the screening of microbiology culture plates collected during environmental monitoring; and APAS PharmaQC, an artificial intelligence for culture plate reading. It also develops APAS intelligent imaging technology for various applications, which includes wound treatment, histopathology, and antimicrobial susceptibility testing.
Clever Culture Systems Limited Fundamentals Summary
| LBT fundamental statistics | |
|---|---|
| Market cap | AU$29.87m |
| Earnings (TTM) | -AU$3.74m |
| Revenue (TTM) | AU$1.26m |
23.8x
P/S Ratio-8.0x
P/E RatioIs LBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBT income statement (TTM) | |
|---|---|
| Revenue | AU$1.26m |
| Cost of Revenue | AU$149.00k |
| Gross Profit | AU$1.11m |
| Other Expenses | AU$4.85m |
| Earnings | -AU$3.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0021 |
| Gross Margin | 88.14% |
| Net Profit Margin | -297.77% |
| Debt/Equity Ratio | 71.9% |
How did LBT perform over the long term?
See historical performance and comparison